Effects of amphetamine on subcellular distribution of dopamine and DOPAC
Abstract
Amphetamine effects on distribution of dopamine, 3,4-dihydroxyphenylacetic acid (DOPAC), and amphetamine in vesicular, cytosolic, and extracellular compartments associated with a striatal varicosity were estimated through use of a computer simulation model. In addition, contribution to overall effects of amphetamine by each of five actions--transport by dopamine transporter (DAT), transport by vesicular monoamine transporter, stimulation of reverse transport, inhibition of monoamine oxidase (MAO), and slowing of dopamine cell firing rate--were evaluated. Amphetamine enters a varicosity almost entirely by DAT and accumulates to very high levels within the varicosity. Both reverse transport by DAT and passive diffusion contribute to continual amphetamine egress across the plasma membrane. Amphetamine enters storage vesicles by both transport and diffusion. The transport portion competes with dopamine storage, resulting in redistribution of approximately half of dopamine from vesicles to cytosol. The high concentration of amphetamine in the cytosol inhibits MAO, protecting cytosolic dopamine. A very small fraction of cytosolic dopamine is moved to extracellular compartment via reverse transport by DAT. The amount of dopamine moved by reverse transport is limited because of competition by very high cytosolic levels of amphetamine. In the presence of amphetamine, rate of dopamine transfer to extracellular compartment is less than control; however, high levels of extracellular dopa…
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
D-amphetamine has been proven to decrease MAO activity in striatal tissue, contributing to a reduction in DOPAC and final metabolite HVA reduction.
“D-amphetamine has been proven to decrease MAO activity in striatal tissue (56), contributing to a reduction in DOPAC and final metabolite HVA reduction.”
Cites
Sulzer, D., Chen, T., Lau, Y., Kristensen, H., Rayport, S., & Ewing, A. (1995) · The Journal of Neuroscience · doi:10.1523/jneurosci.15-05-04102.1995 · Cited by 688 · see citing works
Tyrosine hydroxylase phosphorylation: Regulation and consequences
Dunkley, P. R., Bobrovskaya, L., Graham, M. E., Von Nagy‐Felsobuki, E. I., & Dickson, P. W. (2004) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2004.02797.x · Cited by 455 · cited 2× · see citing works
“…activity are end product inhibition by elevated levels of dopamine in the cytosol (Kilts et al., 1987; Nagatsu et al., 1964) and phosphorylation of serine 140 regulated by activation of dopamine D2 receptors on the axon terminal (Dunkley et al., 2004; Lindgren et al., 2003; Lindgren et al., 2001).”
Background
Flagged first, then by citations
Cited by
Sorted by citations
Jian-min, C., Zhi-yuan, W., Shi-xuan, W., Rui, S., Ning, W., & Jin, L. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.885574 · Cited by 7 · see citing works
“D-amphetamine has been proven to decrease MAO activity in striatal tissue (56), contributing to a reduction in DOPAC and final metabolite HVA reduction.”
Background
- Authors
- Wallace, L. J.
- Affiliations
- The Ohio State University (US)
- Corresponding author
- Wallace, Lane J.
- ORCID
- Wallace, Lane J.
- Venue
- Synapse
- Publisher
- Wiley
- Published
- 2012-03-27
- Volume
- 66
- Issue
- 7
- Pages
- 592-607
- ISSN
- 0887-4476 (ISSN-L)
- 1098-2396
- OpenAlex
- W2049204004
- Cited by
- 11
- References
- 2
- Citations by year
- 2022: 2 · 2020: 1 · 2019: 2 · 2016: 2 · 2015: 2 · 2013: 2
- FWCI
- 0.53
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Synapse (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Health Sciences › Medicine › Neurology › Parkinson's Disease Mechanisms and Treatments
- Keywords
- amphetamine, dopamine, DOPAC, dopamine transporter, reverse transport, vesicular monoamine transporter, monoamine oxidase inhibition, subcellular localization, computer simulation model, dopamine reuptake
- MeSH terms
- Amphetamines, Computer Simulation, Corpus Striatum, Dopamine, Models, Neurological, 3,4-Dihydroxyphenylacetic Acid, Intracellular Space, Dopamine Plasma Membrane Transport Proteins, Vesicular Monoamine Transport Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review